Zomedica Corp Stock Price, News & Analysis

Zomedica Corp. (NYSE American: ZOM) has been appointed as the Official Shock Wave Therapy Supplier for the United States Equestrian Team Veterinarians through its PulseVet division. PulseVet specializes in electro-hydraulic shock wave technology, aimed at treating various conditions in veterinary patients. The USEF highlighted the partnership's commitment to enhancing horse welfare. The PulseVet system is clinically proven for treating muscle injuries, osteoarthritis, and more. This collaboration emphasizes Zomedica’s role in veterinary health and aligns with its mission to support animal wellness.

Zomedica Corp. (NYSE American: ZOM) announced its participation in the Animal Health, Nutrition & Technology Innovation USA event in Boston from June 21-23, 2022. Greg Blair, Vice President of Business Development, will discuss how Zomedica's innovative products and technologies are assisting veterinarians in adapting to post-COVID challenges. This forum offers insights into emerging trends in animal health and provides networking opportunities with industry executives. Zomedica focuses on creating diagnostic and therapeutic products for companion animals.

Zomedica Corp. (NYSE American: ZOM) has announced a definitive agreement to acquire substantially all assets of Revo Squared LLC. This acquisition includes Revo's MicroView digital cytology platform, which enhances veterinary diagnostic capabilities by automating slide preparation, thus reducing human error. The transaction aims to improve efficiency within veterinary practices and is expected to close within 30 days. Executives from Revo will join Zomedica to facilitate integration and manufacturing, expanding Zomedica's product offerings for companion animal care.

Zomedica Corp. (NYSE American: ZOM) has commenced a study to evaluate shock wave therapy for treating Exercise Induced Pulmonary Hemorrhage (EIPH) in horses. Conducted by Dr. Beau Whitaker, the study currently involves eight horses and aims to assess bleeding episodes and performance improvements in barrel racing horses before and after therapy. As EIPH is common in performance horses and current treatments are limited, this research could offer a significant breakthrough in veterinary care. Zomedica's PulseVet technology is a leader in shock wave therapy, enhancing recovery for various conditions.

Zomedica Corp. (NYSE American: ZOM) announced that CEO Larry Heaton will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 12:30 pm ET. The presentation will provide a corporate overview and update on the company’s initiatives in veterinary health, particularly focused on diagnostics and therapeutic products for companion animals. Interested parties can access the live webcast here and find more details on Zomedica's website.

Zomedica Corp. (NYSE American: ZOM) appointed Karen DeHaan-Fullerton as General Counsel and Corporate Secretary effective May 31, 2022. With over 20 years of corporate legal experience, she will focus on building strategy across regulatory, risk, and compliance functions. CEO Larry Heaton welcomed her expertise as a boost to the executive team. DeHaan-Fullerton expressed enthusiasm for contributing to Zomedica's mission in veterinary health, which emphasizes innovative diagnostics and medical devices for companion animals.

Zomedica Corp. (NYSE American: ZOM) announced a strategic investment of $1 million in Structured Monitoring Products, Inc. This investment includes acquiring a convertible note and an option to act as a sales agent for the VetGuardian monitoring platform, which offers real-time remote monitoring of pets without wires. The collaboration aims to enhance veterinary care, particularly during recovery periods. The deal is subject to further negotiations and agreements, underscoring Zomedica's commitment to innovative veterinary solutions.

Zomedica Corp. (NYSE American: ZOM) reported a strong first quarter, with a 38% year-over-year revenue growth and maintaining 74% gross margins. Cash burn decreased to $2.6 million, with $192 million in cash remaining. The sales force launch of the PulseVet product saw a 500% increase in revenue. The company focuses on enhancing veterinary workflow and profitability through innovative diagnostic and therapeutic products, with strategic plans for market penetration and acquisitions.

Zomedica (NYSE American: ZOM) reported consolidated financial results for Q1 2022, showing significant growth in revenue to $3.8 million, compared to $14,000 in Q1 2021. The gross margin improved to 74% from 60%, driven largely by the PulseVet platform, which recorded $3.7 million in revenue. Unit sales to small animal veterinarians surged 500% year-over-year. However, the company posted a net loss of $3.9 million for the quarter. As of March 31, 2022, Zomedica had $192.3 million in cash and equivalents.